Last reviewed: May 28, 2026

Last updated: May 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists for weight loss typically follow a titration schedule beginning at 0.25 mg subcutaneously once weekly, escalating every four weeks up to 2.4 mg weekly. However, the 'right dose' is not a one-size-fits-all number—it depends on clinical response, tolerability, and individual metabolic factors.

Understanding how dosing works, what biomarkers matter, and why some individuals respond differently at different doses can help you approach a provider conversation with informed perspective. PlexusDx focuses on precision wellness: genetic and metabolic context may help personalize your pathway forward.

Standard GLP-1 Dosing Protocols for Weight Loss

Semaglutide for weight loss (Wegovy) follows a four-week titration: 0.25 mg week one, 0.5 mg week five, 1 mg week nine, and 1.7 mg week thirteen, with 2.4 mg as the target maintenance dose. This gradual escalation allows the body to adjust and helps minimize gastrointestinal side effects.

Some patients achieve meaningful weight loss at 1.0–1.7 mg weekly and choose to remain at those doses due to tolerability or individual response. Medical literature suggests 2.4 mg weekly produces approximately 20–22% weight loss, while lower doses yield 10–15% reduction. Provider guidance on your specific threshold is essential.

Dosing Factors: Biomarkers, Genetics, and Individual Response

Your optimal GLP-1 dose depends on several overlapping factors: baseline metabolic markers, genetic predispositions in GLP-1 signaling pathways, gastrointestinal tolerance, comorbidities, and concurrent medications. A 0.25 mg dose may achieve significant response in one individual but require 2.4 mg in another.

Dosing Consideration Clinical Relevance
GLP1R genetic variants Variants like rs6923761 may influence receptor sensitivity and dose response trajectory
GIPR pathway activity rs1800437 polymorphisms may affect incretin-mimetic responsiveness
Baseline metabolic markers HbA1c, insulin resistance, and BMI inform starting dose and escalation pace
Gastrointestinal tolerance Nausea severity at each step may indicate slower titration or dose plateau
Renal and hepatic function Clearance capacity influences both dose and safety monitoring intervals
Concurrent medications Drug interactions may require dose adjustments or closer clinical oversight

Dose Plateau and Finding Your Effective Window

Not all patients require 2.4 mg weekly. Clinical practice shows that some individuals reach their weight loss and metabolic goals at 1.0–1.7 mg and experience diminishing returns or increased side effects at higher doses. 'Effective dose' is the lowest amount producing your desired clinical response with tolerable side effects.

Your provider may recommend holding at an intermediate dose if you're experiencing good results and good tolerability. Real-world data and your own tracking of appetite, satiety, and gastrointestinal symptoms help inform these conversations. Dose increases should align with measurable clinical goals and safety tolerance.

Who Benefits from Dose Escalation and Provider Oversight

Candidates for full-dose GLP-1 therapy typically have a BMI ≥30 (or ≥27 with weight-related comorbidities), established metabolic dysfunction, or type 2 diabetes requiring glycemic control. However, not every patient requires or tolerates the maximum dose—risk factors include kidney disease, history of thyroid cancer, severe gastroparesis, or pregnancy.

Your provider will assess whether you are a suitable candidate, monitor for side effects at each dose level, and personalize your trajectory. Genetic testing and metabolic biomarkers can provide supportive context for these conversations, but clinical judgment and direct patient-provider dialogue remain central to safe, effective dosing.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in GLP-1 and GIPR signaling pathways—such as GLP1R rs6923761 and GIPR rs1800437—that may help provide context for how your body processes incretin-mimetic signals. These predispositions may inform discussions with your provider about whether you might respond optimally at a particular dose or formulation.

The genetic test does not predict your exact medication response or guarantee which dose will work best; rather, it reveals predispositions in peptide signaling pathways. Interpreted alongside your biomarkers (HbA1c, lipid panel, insulin resistance markers) and clinical history, this information can support a more personalized conversation with your healthcare provider about dosing strategy.

Whether you choose branded semaglutide, compounded formulations, or oral variants, understanding your genetic context and biomarker profile empowers a more informed, collaborative decision-making process with your provider about the dose, frequency, and compound best suited to your metabolism and lifestyle.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves